Immunocore Holdings plc
NASDAQ: IMCR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bahija Jallal
- Employees
- 493
- Headquarters
- Abingdon, United Kingdom
- IPO year
- 2021
- Market cap
- $1.5B
- Website
- https://www.immunocore.com
Loading IMCR…
Loading profile data…Frequently asked questions about IMCR
What does Immunocore Holdings plc (IMCR) do?
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its cu...
Where does IMCR trade?
Immunocore Holdings plc (IMCR) trades on the NASDAQ Global Select.
What sector is IMCR in?
Immunocore Holdings plc (IMCR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immunocore Holdings plc?
Bahija Jallal is the chief executive officer of Immunocore Holdings plc (IMCR).
Where is Immunocore Holdings plc headquartered?
Immunocore Holdings plc is headquartered in United Kingdom.
Does IMCR pay a dividend?
Immunocore Holdings plc (IMCR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMCR go public?
Immunocore Holdings plc (IMCR) completed its initial public offering in 2021.
Is IMCR an ADR?
Yes — IMCR is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Immunocore Holdings plc reporting and dividends follow the underlying issuer.